No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. [electronic resource]
Producer: 20190221Description: e0203200 p. digitalISSN:- 1932-6203
- Adult
- Aged
- Antigens, CD -- blood
- Antigens, Differentiation, Myelomonocytic -- blood
- Biomarkers -- blood
- Collagen Type III -- blood
- Collagen Type IV -- blood
- Double-Blind Method
- Female
- Gastrointestinal Agents -- therapeutic use
- Humans
- Lectins, C-Type -- blood
- Liver Cirrhosis -- blood
- Male
- Mannose Receptor
- Mannose-Binding Lectins -- blood
- Middle Aged
- Receptors, Cell Surface -- blood
- Rifaximin -- therapeutic use
- Severity of Illness Index
- Treatment Outcome
- CD163 Antigen
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.